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Abstract
Background: Shared medical appointments are a series of one-to-one doctor-patient contacts, in presence of a
group of 6-10 fellow patients. This group visits substitute the annual control visits of patients with the neurologist.
The same items attended to in a one-to- one appointment are addressed. The possible advantages of a shared
medical appointment could be an added value to the present management of neuromuscular patients. The
currently problem-focused one-to-one out-patient visits often leave little time for the patient’s psychosocial needs,
patient education, and patient empowerment.
Methods/design: A randomized, prospective controlled study (RCT) with a follow up of 6 months will be
conducted to evaluate the clinical and cost-effectiveness of shared medical appointments compared to usual care
for 300 neuromuscular patients and their partners at the Radboud University Nijmegen Medical Center. Every
included patient will be randomly allocated to one of the two study arms. This study has been reviewed and
approved by the medical ethics committee of the region Arnhem-Nijmegen, the Netherlands. The primary
outcome measure is quality of life as measured by the EQ-5D, SF-36 and the Individualized neuromuscular Quality
of Life Questionnaire. The primary analysis will be an intention-to-treat analysis on the area under the curve of the
quality of life scores. A linear mixed model will be used with random factor group and fixed factors treatment,
baseline score and type of neuromuscular disease. For the economic evaluation an incremental cost-effectiveness
analysis will be conducted from a societal perspective, relating differences in costs to difference in health outcome.
Results are expected in 2012.
Discussion: This study will be the first randomized controlled trial which evaluates the effect of shared medical
appointments versus usual care for neuromuscular patients. This will enable to determine if there is additional
value of shared medical appointments to the current therapeutical spectrum. When this study shows that group
visits produce the alleged benefits, this may help to increase the acceptance of this innovative and creative way of
using one of the most precious resources in health care more efficiently: time.
Trial registration: DutchTrial Register http://www.trialregister.nlNTR1412
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Background
Introduction
As of January 2006, the department of neurology at the
RUNMC has started offering shared medical appoint-
ments or group visits to patients with a neuromuscular
disease. This novel approach of delivering outpatient
care is now being compared with usual care during a
randomized controlled trial with 300 patients and their
partners. The focus in this trial is on health outcomes
and costs.
Motive
Most neuromuscular diseases are chronic progressive
diseases necessitating periodic specialized care. Because
of the progressive nature of the disease, existing symp-
toms aggravate over time and new symptoms may
develop over time, requiring adjustment of management,
and giving rise to new questions on the part of the
patient and his or her partner. In the absence of defini-
tive cures for chronic neuromuscular diseases, the
improvement of quality of life, patient- and partner
satisfaction with care, self management and functional
capacity become key objectives of care. Currently, these
patients attend the out-patient clinic at regular intervals
(usually annually), where they are seen in one-to-one
patient- physician encounters. It is difficult, however, to
fulfill the complex needs of neuromuscular patients in
these brief, problem-focused out-patient visits which
leave little time for the patient’s psychosocial needs,
patient education, and patient empowerment. The possi-
ble advantages of a shared medical appointment could
be an answer to these questions. Our hypotheses are
that shared medical appointments show 1) the same
effect on the development of the disease as individual
appointments 2) an improvement of self-efficacy as
opposed to individual appointments, therefore resulting
in an improved quality of life 3) better use of resource
utilization and 4) a positive effect on self efficacy and
quality of life of the partner as well as on the relation-
ship [1-6].
What is a shared medical appointment?
During a shared medical appointment or group visit,
6-10 patients and their partners are seen simulta-
neously by a physician who is supported by a group
mentor. Shared medical appointments are a series of
one on one doctor-patient contacts, in presence of a
group fellow patients. A group visit takes 1,5 - 2
hours and substitutes the annual control visit of the
patients. The same items the neurologist attends to in
a one to one appointment are addressed. The physi-
cian has more time to give information and patients
and partners can ask questions to- and learn from
their fellow patients. The group mentor facilitates the
group process, fosters interaction between patients
and manages time. Shared medical appointments
should not be confused with group education or peer
support groups. As opposed to a group visit, these
meetings do not substitute for the periodic consulta-
tion with the clinician [7,8].
Experience with shared medical appointments in
patients with diabetes, heart failure, bone marrow
transplantation and chronically ill older patients have
been reported [9-14]. Evidence of group visits for neu-
rological patients is at this moment at the level of a
feasibility trial for patients with Parkinson disease
[15].
Methods/design
A randomized, prospective controlled study (RCT) with
a follow up of 6 months will be conducted to evaluate
the clinical and cost-effectiveness of shared medical
appointments compared to usual care for neuromuscu-
lar patients. The trial flow of the proposed subject
enrolment and randomization procedures are shown in
Figure 1.
Study population
The aim is to include 270 evaluable patients with one
of the following chronic neuromuscular diseases:
- Myotonic Dystrophy type 1 genetically determined
(classic and juvenile type) [16];
- McArdles disease, Glycogen Storage Disease Type
V. Biochemically and genetically determined;
- Facioscapulohumeral Muscular Dystrophy (FSHD),
genetically determined;
- Chronic progressive external ophthalmoplegia
(CPEO) as defined by Emery [17];
- Oculopharyngeal Muscular Dystrophy (OPMD),
genetically determined;
- Inclusion body myositis (IBM) as defined by Badris-
ing and Verschuuren [18,19]
- Non-dystrophic myotonias. These skeletal muscle
channelopathies include two main groups: the chloride
and sodium channelopathies [20];
- Myositis: Dermatomyositis and Polymyositis [21]
- Polyneuropathy: CMT1 and HNPP [22]
The partners of these patients will also be included.
All patients will be identified by CRAMP, a neuromus-
cular database containing data from over 4500 patients
with neuromuscular disease attending the outpatient
clinic of the Radboud University Nijmegen Medical
Center [23]. From this database, patients who meet the
inclusion criteria (table 1) will be contacted by tele-
phone by the primary investigator (FS) to inform them
about the study and ask permission to send information
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and informed consent forms. If the patient decides not
to participate in the study, the reason will be asked and
documented. If written consent forms are not returned
within 3 weeks, patients will receive a reminder phone
call. After written informed consent is obtained, patients
and their partners are randomized to one of the two
study arms. Reasons for drop-out will be asked and
documented.
Screening and recruitment
Inclusion and
randomization
Baseline measurements:
Intervention group:
shared medical
appointment
Control group:
Individual outpatient
appointment
T1 questionnaires
T2 questionnaires
T1 questionnaires
T2 questionnaires
T=pre
T=0
T=3
T=2
T=1
CRAMP database
T3 questionnaires T3 questionnaires
Questionnaires:
?? Use of care
?? General health (SF 36,
eQ5D, INQOL)
?? Self efficacy, social support,
relationship
Questionnaires:
?? General health (SF 36,
eQ5D, INQOL)
?? Self efficacy, social support,
relationship
?? Satisfaction
Questionnaires:
?? Use of care
?? General health (SF 36,
eQ5D, INQOL)
?? Self efficacy, social support,
relationship
?? Satisfaction
1 week
3 months
3 months
Questionnaires:
?? Use of care
?? General health (SF 36,
eQ5D, INQOL)
?? Self efficacy, social support,
relationship
?? Satisfaction
Figure 1 flowchart of trial design. CRAMP database: Computer Registry of All Myopathies and Polyneuropathies. INQOL: Individualized
Neuromuscular Quality of Life.
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Ethical approval and registration
This study has been reviewed and approved by the med-
ical ethics committee of the region Arnhem-Nijmegen,
the Netherlands. (reference CMO nr. 2008/224) and has
been registered in the NTR (Dutch Trial Registration nr
NTR1412) Patients and their partners receive verbal and
written information about the study and written
informed consent will be obtained before randomization.
Randomization and blinding
Concealed randomization will be performed through
computer-generated randomization software. Every
included patient will be randomly allocated to one of
the two study arms by the computer. The method of
simple randomization is applied. In view of the nature
of the interventions, blinding of the participants, partici-
pating neurologists and primary researcher is not possi-
ble. The statistician who conducts the analysis of the
data will, however, be blinded for the patients’ groups.
Interventions
Care as usual: individual outpatient appointment.
Patients and partners who are randomized to the con-
trol group will have their regular control visit with one
of the participating neuromuscular neurologists at the
outpatient neurology department of the RUNMC. This
one on one control visit substitutes the regular annual
control visit the patients pay to the neurology depart-
ment. The same items that are normally attended to
during the control visit, are attended to by the neurolo-
gist. All physical examinations, prescriptions and refer-
rals are conducted as deemed appropriate, and
documented in the patient record. The regular one on
one control visit takes 30 minutes.
Intervention: shared medical appointment
Patients and partners who are randomized to the inter-
vention arm of the study will be invited to a shared medi-
cal appointment of 1,5 - 2 hours with one of the
participating neuromuscular neurologists and a group
mentor at the outpatient neurology department of the
RUNMC. The same neurologists execute the individual
appointments and the shared medical appointments. As
well as for the individual appointments, the shared medical
appointments substitute for the annual control visit of the
patients. The same items the neurologist attends to in a
one on one control visit are attended to during the shared
medical appointment. The neurologist is supported by a
group mentor, who facilitates the group process, fosters
interaction between patients and manages time.
The group mentor starts with a short introduction in
which the process of the shared medical appointment is
explained and confidentiality is emphasized. Patients
and their partners are asked to fill out a privacy form,
which is kept in the patient’s records, in order to
emphasize the confidentiality of the group visit. If physi-
cal examinations are deemed necessary, they are con-
ducted in a private examination room close to the
group visit room directly after the shared medical
appointment. Necessary prescriptions, referrals, and
chart notes are being taken care of during or directly
after the shared medical appointment. The neurologists
have received training in conducting shared medical
appointments prior to the study. The process of the
shared medical appointments is described in appendix 1.
Table 1 inclusion and exclusion criteria
Inclusion criteria
1. Registered in CRAMP database with one of the following neuromuscular diseases
➢ Myotonic Dystrophy type 1. genetically proven (classic and juvenile type)
➢ McArdles disease, Glycogen Storage Disease Type V. Biochemically and genetically proven
➢ Facioscapulohumeral Muscular Dystrophy (FSHD). genetically determined
➢ Chronic progressive external ophthalmoplegia (CPEO) as defined by Emery
➢ Oculopharyngeal Muscular Dystrophy (OPMD). genetically determined
➢ Inclusion body myositis (IBM)as defined by Badrising and Verschuuren.
➢ Non-dystrophic myotonias. These skeletal muscle channelopathies include two main groups: the chloride and sodium channelopathies.
➢ Myositis: Dermatomyositis and Polymyositis
➢ Polyneuropathy: CMT1 & HNPP
2. Age > 18 years
3. Patients and their partners are control patients in care at the department of neurology RUNMC
Exclusion criteria
1. Patients or partners with severe hearing problems
2. Patients or partners who cannot speak, read or understand the Dutch language well
3. Patients and their partner who have had a control visit with a neurologist at the neurology department of the RUNMC less than 6 months ago
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Compliance and attrition
When participants indicate that they wish to discontinue
their participation in the study, reasons will be
documented.
Outcomes
Outcome measures for patients are listed in table 2. The
primary outcome measure is quality of life (daily activity
limitations, pain, mood, fatigue, social activities) as mea-
sured by the EQ-5D, SF-36 and the Individualized neuro-
muscular Quality of Life Questionnaire (INQoL). For the
SF-36 and EQ 5 D, normative scores are available based
on the Dutch population. For the INQoL, no Dutch
version was available. With granted authorization from the
authors, a translation into the Dutch language was made
[24-27]. Secondary outcome measures are (1) Use of
health care resources (use of health care services, medica-
tion, compliance with medication, use of assistance with
daily activities) Questions from the Client Service Receipt
Inventory (CSRI) are used to record service utilization
[28]. (2) Self efficacy (how much confidence one has in
being able to execute specific behaviour), as measured by
the Self Efficacy questionnaire from Schwarzer [29]. This
is a 10-item psychometric scale that is designed to assess
self-beliefs to cope with a variety of difficult demands in
life. Also, a questionnaire to measure self efficacy of
patients with neuromuscular disease was developed by the
research group. (3) The need for social support was
assessed by using the subscale emotional support of the
Dutch questionnaire SSLD (Sociale Steun Lijst-Discrepan-
ties) from Sanderman and van Sonderen [30]. (4) Satisfac-
tion with relationship was measured by asking the
participants to rate their relationship on a 1/10 scale and
to rate their relationship on a VAS scale, ranging from the
worst possible relationship to the best possible relationship
[31] (5) Satisfaction with and aspects of the visit, as
measured by The QUality Of care Through the patient’s
Eyes (QUOTE) questionnaire [32]. The severity of the dis-
ease as measured through the Rankin-scale is assessed
during the shared medical appointments and through
reviewing the chart notes for individual appointments by
the participating neurologists or primary researcher
[33,34].
Outcome measures for partners are listed in table 3.
Among partners of patients, quality of life (EQ-5D)
[24-27], self efficacy (SE questionnaire by Schwarzer,
[29]), the need for social support (subscale emotional
support of the Dutch questionnaire SSLD [30], satisfac-
tion with the relationship (VAS scale and 1-10 report-
ing)[31], objective burden of care and satisfaction with
and aspects of the visit (QUOTE questionnaire, [32])will
be measured. Ojective burden of care is measured by
asking after the amount of time a partner spends on
caring for the partner and on doing household tasks in
order to be able to relieve or support their partner with
the chronic disease; time spent on delivering care for
the chronically ill partner is the main predictor for the
impact of the disease on the life of the partner [35].
Economic evaluation
Cost effectiveness will be assessed from a societal per-
spective. Direct neuromuscular disease-related costs
health care costs, including costs of outpatient care,
physical-, speech- and occupational therapy, additional
visits to other health care providers (GPs, specialist care,
etc.), district nursing, receipt of aids and adaptations,
prescription medication, professional home care and
hospitalization will be included, as well as non-health
care costs such as costs for paid and unpaid help. For
unit cost prices, standard rates will be adopted from the
national guideline [36] or real cost prices (e.g., for medi-
cation) will be obtained through the website of the
Dutch Health Care Insurance Board (CVZ, http://www.
medicijnkosten.nl). For shared medical appointments, a
cost price will be calculated on the basis of available
standard rates and real expenditures. The price year will
be 2009, the currency Euros, and in view of the time-
scale of the study, costs and health benefits will not be
discounted. Utilization of itemized resources over the
Table 2 Outcome measures and instrumentation patients
Instruments T0 T1 T2 T3
Primary outcome measures
Quality of life EQ5D, SF36, INQOL √ √ √ √
Secondary outcome measures
Demographic statistics √
Severity of the disease Rankin Scale √
Use of care resources and medicine Client Service Receipt Inventory (CSRI) √ √ √
Self efficacy SE questionnaire from Schwarzer, SE NMD √ √ √ √
Social support SSLD (Sociale Steun Lijst-Discrepanties) √ √ √ √
Satisfaction with relationship √ √ √ √
Satisfaction with the appointment QUality Of care Through the patient’s Eyes (QUOTE) √ √ √
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trial period will be self-recorded by patients with a mod-
ified version of the Client Service Receipt Inventory
(CSRI)[28]. Costs per patient will be calculated by multi-
plying resource volumes by unit costs.
Outcome measures will be obtained through standar-
dized questionnaires, who patients and partners fill out
at home at the start of the study period (T0), 1 week
(T1), 3 months (T2) and 6 months after the intervention
(T3). See Figure 1 and table 2 and 3. At the first mea-
surements (T0) demographic data will be obtained.
Statistical analysis
Sample size
On the basis of the literature [37,38] group visits may be
expected to lead to a clinically relevant improvement in
quality of life of 5 points on the total SF-36 score.
Assuming a standard deviation of 12 [39], 92 patients
need to be enrolled in both groups to achieve a statisti-
cal power of 80% (alpha = 0.05, two-sided). Taking into
account non-evaluable patients, to adjust for imbalances
and to be able to do subgroup analysis on age, sex, gen-
der and severity, 135 patients will be enrolled in both
groups. In order to be able to evaluate 270 patients, the
aim is to include 300 patients.
Analysis of outcome measures
300 neuromuscular patients and if applicable their part-
ners will be included in the study. The primary analysis
will be an intention-to-treat analysis on the area under
the curve of the quality of life scores (average response
during 6 months). A linear mixed model will be used
with random factor group and fixed factors treatment,
baseline score and type of neuromuscular disease. Other
outcome parameters will be evaluated in a similar way
and additional per protocol analyses will be carried out.
For the analyses SPSS version 17 statistical software
will be used. A p-value of 0.05 will be considered statis-
tically significant. Missing data will be imputed using
multiple imputation techniques.
Economic evaluation
An incremental cost-effectiveness analysis will be con-
ducted from a societal perspective, relating differences
in costs to difference in health outcome as measured by
the Euroqol-5D, an instrument to evaluate different
health states. Bootstrapping will be used for pair-wise
comparisons in direct health care costs, direct non-
health care costs, total direct costs, total indirect costs,
and total costs between the two groups. Confidence
intervals will be obtained by conventional re-sampling
methods (bootstrapping). The cost effectiveness analysis
will provide information on the marginal costs and
effects of shared medical appointments relative to con-
ventional one-to-one outpatient visits through the calcu-
lation of an incremental cost effectiveness ratio. Ratios
will include the primary outcome of the trial, i.e., quality
of life and two secondary outcome parameters; func-
tional activities, and self-efficacy. Cost acceptability
curves will be calculated showing the probability that
the shared medical appointment is cost effective at spe-
cified ceiling ratios. In situations where there is no sig-
nificant difference in effects, the use of cost-
minimization analysis will be used for the reporting of
cost differences only. Sensitivity analyses will be con-
ducted, exploring the sensitivity of the conclusions to
various sources of uncertainty, including sampling varia-
tion (e.g., differences in self-efficacy and functional abil-
ities in both groups) and point-estimates (e.g., unit cost
prices of major cost drivers).
Discussion
To the best of our knowledge, this study will be the first
randomized controlled trial which evaluates the effect of
shared medical appointments versus usual care for neu-
romuscular patients. Evidence shows that shared medical
appointments can have substantial added value, deriving
not only from sharing a health care professional’s time,
but also from sharing mutual experiences, particularly for
patients with a chronic disease [2,3,40]. In the literature,
group visits have been shown to result in fewer hospitali-
zations and emergency visits, increased patient satisfac-
tion and increased self-efficacy as compared to usual
one-to-one outpatient visits in elderly, chronically ill
patients (Scott et al. 2004). In patients with diabetes, a
Table 3 Outcome measures and instrumentation partners
Instruments T0 T1 T2 T3
Primary outcome measures
Quality of life EQ5D √ √ √ √
Secondary outcome measures
Demographic statistics √
Self efficacy SE questionnaire from Schwarzer √ √ √ √
Social support SSLD (Sociale Steun Lijst-Discrepanties) √ √ √ √
Satisfaction with relationship √ √ √ √
Satisfaction with the appointment QUality Of care Through the patient’s Eyes (QUOTE) √ √ √
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randomized controlled trial demonstrated an increased
frequency of preventive procedures among patients
attending group visits, resulting in a better general health
status as measured by the SF-36 [3]. Sadur et al (1999)
demonstrated greater satisfaction with diabetes care,
greater self-efficacy, better glycemic control, and lower
service utilization among patients with diabetes who
were randomly allocated to group visits as compared to
counterparts who were allocated to usual care.
This study has several strengths. Firstly, shared medi-
cal appointments will be compared with usual care in a
randomized design. This will enable to determine if
there is additional value of shared medical appointments
to the current management spectrum. Secondly, this
study involves measuring effect of a treatment on part-
ners of patients with a neuromuscular disease. Studies
from Baanders et al (2007) and Timman (2010) show
that living with a chronically ill person, specifically with
a neuromuscular disorder, has an impact on the part-
ner’s life that goes beyond the consequences of care giv-
ing, for example consequences on personal life strain,
social relations, financial burden, and intrinsic rewards
[35]. And that marital satisfaction is a strong predictor
of better wellbeing, both for patients and, even more so,
for partners [31]. Thirdly, this study aims to determine
the cost effectiveness of shared medical appointments as
compared to care as usual. In current healthcare time is
a scarce good. Efficiency goals are on top of every
healthcare managers’ list. When introducing a new way
of delivering care, such as shared medical appointments,
this preferably is just as or even more efficient than care
as usual. Therefore it is important to take cost effective-
ness of the intervention into account in this study. A
limitation of this study can be the fact that it is a single
center study. This may influence the transferability of
the research results to other hospitals. Due to pragmatic
and financial reasons the follow up time is limited to 6
months. For patients with neuromuscular disorders
annual control visits are offered, this limits the number
of shared medical appointments a patient receives dur-
ing the study to one. Possibly the effect of group visits
increase when attended several times. With this study
design it is not possible to show this effect. A reflection
of practice in this study, that could be a possible limita-
tion, is inclusion of different patient groups. Although
patients all have a chronic neuromuscular disease, possi-
ble differences in effects between patient groups could
be difficult to show with this study design.
In conclusion, this study will provide greater insight in
the (cost) effectiveness of shared medical appointments
for neuromuscular patients. The concept of group visits
or shared medical appointments is a typical example of
organizing the delivery of health care in a different way,
in an attempt to improve patient outcome within the
limits of available resources. Many attempts at increas-
ing efficiency of health care consist of reducing the
amount of time health care professionals spend on spe-
cific activities. Such attempts risk, however, to jeopar-
dize the quality of care [41]. When our study shows that
group visits produce the alleged benefits, this may help
to increase the acceptance of this innovative and crea-
tive way of using one of the most precious resources in
health care more efficiently: time.
Appendix 1
Process of a shared medical appointment:
- Patient registers at the outpatient clinic an led to the
group visit room by the group mentor
- Patients are being asked to fill out a privacy form
- Group mentor starts with a brief introduction, in which
the process of an SMA and privacy aspects are explained
- Neurologist starts with consulting the first patient
- Individual medical needs and questions of the
patient are being discussed with the neurologist
- The neurologist gives information to the patient and
his/her partner
- If applicable, the group mentor asks if fellow patients
have experiences on this subject they want to share or
questions they want to ask to fellow patients or the
neurologist
- Neurologist finishes consultation with the first
patient and writes notes in the patient record
- The neurologist lifts the second patient record and
starts with consulting the second patient, and so on till
all patients have had their consultation
- The group mentor asks if all questions are answered
and if so closes the group visit
- If applicable, physical examination of a patient is
being executed by the neurologist in a separate room,
any necessary receipts or blood samples are being taken
care of as well
- Group mentor and neurologist leave the group visit
room and fill out patient records and patient letters
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